ABBV
What one share of AbbVie holds
Pharmaceutical Preparations
AbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. This operating structure enables the Chief Executive Officer, as Chief Operating Decision Maker (CODM), to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals.
AbbVie’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $36.30 |
|---|---|
| Profit | $3.54 |
| Capex (buildings and equipment) | $0.73 |
| Free cash flow | $10.27 |
| Dividends | $6.75 |
| Cash and investments | $3.72 |
| Debt | $40.08 |
| Book value | −$3.36 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $15.72 | $3.63 | $0.29 | $4.02 | $2.35 | $2.91 |
| 2017 | $17.60 | $3.30 | $0.33 | $5.88 | $2.63 | $3.21 |
| 2018 | $21.19 | $3.66 | $0.41 | $8.27 | $3.95 | −$5.73 |
| 2019 | $22.42 | $5.28 | $0.37 | $8.61 | $4.39 | −$5.52 |
| 2020 | $27.38 | $2.72 | $0.48 | $10.04 | $4.84 | $7.40 |
| 2021 | $31.62 | $6.45 | $0.44 | $12.37 | $5.31 | $8.71 |
| 2022 | $32.65 | $6.63 | $0.39 | $13.64 | $5.71 | $9.75 |
| 2023 | $30.64 | $2.72 | $0.44 | $12.44 | $5.99 | $5.86 |
| 2024 | $31.77 | $2.39 | $0.55 | $10.06 | $6.29 | $1.88 |
| 2025 | $34.50 | $2.36 | $0.68 | $10.05 | $6.65 | −$1.85 |